Biogen (Clomifene)

Quick links to important sections

Biogen (Clomifene)

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biogen (Clomifene)

Property Description
Active ingredient Clomifene Citrate
Form Oral Tablet
Pharmacological class Selective Estrogen Receptor Modulator (SERM)
General purpose Ovulation Induction
Origin Synthetic, Nonsteroidal

Biogen is a brand name for a medicine containing the active ingredient clomifene citrate, a synthetic, nonsteroidal compound classified as a Selective Estrogen Receptor Modulator (SERM). This drug works by indirectly modulating the body's natural reproductive hormone systems.


What Type of Medicine is Biogen (Clomifene)?

Clomifene citrate is a prescription-only hormonal modulator that belongs to the pharmacological class of Selective Estrogen Receptor Modulators (SERMs). This classification involves interaction with estrogen receptors, meaning it acts on specific tissues, such as the pituitary gland and hypothalamus. Clomifene is used to cause ovulation in certain women and is administered as an oral agent. The medicine is a single-ingredient product, supplied in tablet form, intended for those experiencing irregular ovulation.


The Composition and Origin of Clomifene

Clomifene is a synthetic triphenyl ethylene derivative, chemically formulated as the citrate salt for stability and oral bioavailability. The substance exists as a racemic mixture of two distinct geometric isomers, zuclomiphene (cis-isomer) and enclomiphene (trans-isomer). Both isomers contribute to the drug's overall therapeutic action. This nonsteroidal, synthetic composition and structural feature influence how it is processed and metabolized by the body.


What is the General Purpose of Clomifene Treatment?

The primary, high-level purpose of clomifene is to act as a synthetic ovulation stimulant. By interrupting the body's natural estrogen feedback loop, the drug causes the brain to increase its release of gonadotropins, including Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH). This intentional hormonal surge is designed to stimulate the ovaries, with the goal of achieving ovulation induction in cases of ovulatory dysfunction.

Regulatory References

  1. Clomiphene: MedlinePlus Drug Information

What side effects are possible with Biogen (Clomifene)?

Possible side effects and safety information

The safety profile of Clomifene Citrate is formally classified by health authorities based on the affected System-Organ-Class (SOC) and the observed frequency of occurrence in clinical use. These classifications define the officially documented risks associated with the medicine.

Frequency-Classified Adverse Reactions

Adverse events are documented by regulatory bodies, with vaso-motor symptoms (hot flushes) classified as Very Common (occurring in ge 1/10 patients). Reactions classified as Common (in 1/100 to <1/10 patients) include headache, visual disturbances (e.g., blurring, scotomata), ovarian enlargement, and abdominal discomfort or nausea. Uncommon events include depression, insomnia, and dizziness. Rare reactions may include optic neuritis or cataract.

Clinically Significant Safety Considerations

Official labeling documents specific serious adverse reactions. The severe form of Ovarian Hyperstimulation Syndrome (OHSS) is a major documented risk. Additionally, reports of severe, and occasionally irreversible visual disturbances, are noted, often requiring careful observation during treatment. The risk of OHSS is generally observed during or shortly after the administration period.

Safety-Related Restrictions and Cautions

The medicine is subject to contraindications that strictly define when it must not be used. It is contraindicated in women who are pregnant, and in individuals with hepatic impairment (liver disease), undiagnosed abnormal uterine bleeding, or ovarian cysts (other than Polycystic Ovarian Syndrome). The label also advises caution for use in patients with pre-existing uterine fibroids due to the potential for enlargement. Regulatory guidelines typically recommend that treatment not exceed six total cycles due to limited safety data beyond that duration.

Overdose and Emergency Response

Overdose and when to seek help

The information below summarizes the officially documented manifestations and required emergency actions for clomifene citrate overdose, based on governmental regulatory sources. All overdose management is supportive, as no specific antidote is known.

Documented Overdose Manifestations

Category Documented Clinical Signs
Ocular/Visual Blurred vision, scotomata (blind spots), scintillating scotomata (visual spots or flashes).
Gastrointestinal Nausea, vomiting, abdominal or pelvic pain, and stomach distension.
Systemic/Pelvic Vasomotor flushes (hot flashes) and ovarian enlargement.

When to Seek Immediate Medical Help

Immediate medical attention is required for any suspected overdose. Emergency services must be contacted immediately if severe or life-threatening symptoms occur, as documented in official regulatory instructions. This urgency is triggered by the presentation of:

  • Collapse
  • Seizure
  • Trouble breathing
  • Inability to be awakened (unresponsiveness)

Regulatory documents state that management includes symptomatic and supportive measures. Gastrointestinal decontamination, such as gastric lavage, may be considered. Increased dose or duration of therapy has been associated with prolonged, sometimes irreversible, visual disturbances, and the potential for chronic nephrotoxicity following prolonged use has been noted.

Therapeutic Uses of Biogen (Clomifene)

Biogen (clomifene) is primarily used in the therapeutic domain of reproductive medicine to address ovulatory dysfunction in women who are seeking pregnancy. It is applied across domains where additional symptomatic support is needed to address ovulatory dysfunction. This means it is used in scenarios where patients experience symptoms related to systemic imbalance that cause irregular or absent ovulation, which are symptoms that interfere with daily functioning.

Clomifene is considered relevant for managing ovulatory dysfunction in women desiring pregnancy. It is used in clinical contexts involving ovulatory instability and assists with maintaining functional stability. This is commonly used across conditions characterized by periods of heightened symptoms like polycystic ovary syndrome (PCOS) or secondary amenorrhea, where symptoms may intensify temporarily due to a lack of a regular menstrual cycle.

The core indications are focused on conditions involving a systemic or localized discomfort related to ovulatory failure or irregular menstrual cycles, which are symptoms that interfere with daily comfort. This is relevant when supportive symptom management is appropriate and contributes to easing the overall symptom load.

“The treatment is applied in clinical settings that involve acute or unstable symptom patterns.”


Quick Fact: Relief for Symptoms related to systemic imbalance


Eligibility and Restrictions for Use

Official Population Eligibility and Restrictions

Biogen, containing clomifene citrate, is officially indicated for adult women with functional ovulatory dysfunction who are seeking pregnancy. Eligibility is strictly defined by a comprehensive list of absolute contraindications that formally prohibit its use in certain populations.

The medicine must not be used by women who are pregnant or by those with liver disease or a history of hepatic dysfunction. Other absolute contraindications include abnormal uterine bleeding of undetermined origin, ovarian enlargement not due to polycystic ovarian syndrome, and the presence of an organic intracranial lesion or uncontrolled thyroid or adrenal dysfunction.

Regulatory documents also define populations where use is limited or restricted. The safety and effectiveness of clomifene citrate have not been established in the pediatric population, and clinical data for the geriatric population is officially insufficient. Caution should be exercised when the medicine is used by patients with uterine fibroids due to the potential for enlargement. Furthermore, use is not established for women who are lactating, as the medicine may reduce lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory interaction profile for Clomifene primarily addresses combinations that result in altered drug exposure or enhanced pharmacodynamic effects. Healthcare professionals are officially constrained by specific interaction mandates outlined in authoritative government documents.

Documented Interaction Constraints

Interacting Agent/Class Interaction Type Regulatory Constraint
Ospemifene Pharmacodynamic Synergism Co-administration is Contraindicated
Benazepril Pharmacodynamic Synergism Use with Caution/Monitor Closely
CYP2D6 and CYP3A4 Inhibitors/Inducers Metabolic Pathway Alteration Potential for altered Clomifene exposure

Co-administration with Ospemifene is officially contraindicated due to the risk of heightened pharmacologic activity from both agents, a consequence of pharmacodynamic synergism. Similarly, Benazepril should be used with caution, as the combination may lead to an increased risk of hypotension.

The active isomers of Clomifene and its metabolites are primarily metabolized by Cytochrome P450 enzymes CYP2D6 and CYP3A4. Consequently, co-administration with strong inhibitors or inducers of these specific enzyme pathways may affect the systemic exposure of Clomifene.

Procedural Monitoring Note

Official labeling specifies the need for periodic monitoring of plasma triglycerides in patients with a preexisting or family history of hyperlipidemia, as an elevated risk of hypertriglyceridemia has been associated with Clomifene treatment.

Mechanism of Action

How Biogen (Clomifene) Works: Mechanism of Action

Clomifene functions as a Selective Estrogen Receptor Modulator (SERM). Its primary action involves competitively binding to estrogen receptors in central neuroendocrine tissues, specifically the hypothalamus and pituitary gland. This binding prevents endogenous estrogen from engaging these receptors, acting as an antagonist at these regulatory sites.

By blocking the estrogen signal, Clomifene leads the hypothalamus to perceive a state of estrogen signaling deficiency, thereby modulating the physiological negative feedback signaling of the Hypothalamic-Pituitary-Gonadal (HPG) axis. This signaling alteration triggers increased pulsatile release of Gonadotropin-Releasing Hormone (GnRH), which influences the subsequent pituitary response.

The heightened GnRH stimulation causes the pituitary to release increased levels of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). These elevated gonadotropins then act directly on the gonads to stimulate the development of ovarian follicles and/or induce the progression of spermatogenesis, resulting in an alteration of the hormonal dynamics within the reproductive axis.

Dosage and Administration Information

How to Use Biogen (Clomifene) — Administration Overview

Clomifene citrate is an oral tablet used in distinct, short-term treatment courses under specialized medical monitoring. The medicine is administered daily for a fixed duration, and the start date is determined by the patient's menstrual cycle.

Administration Scope

Administration Detail Description
Route of Administration Oral tablet.
Initial Dosing 50 mg taken once daily for 5 consecutive days.
Second Course Dosing Increased to 100 mg once daily for 5 days, only if the patient did not ovulate after the initial course.
Maximum Course Duration 5 days at any dose level; treatment is not recommended beyond a total of about six cycles.
Special Populations A lower starting dose may be recommended for patients with Polycystic Ovary Syndrome (PCOS) due to increased sensitivity.

Procedural Administration Timing

The timing of the course initiation is crucial to the administration protocol:

  1. Timing with Bleeding: If spontaneous or progestin-induced bleeding occurs, the five-day course should be started on or about the fifth day of the cycle.
  2. Timing without Bleeding: If the patient has no recent uterine bleeding, the therapy may be started at any time.
  3. Interval: Subsequent courses may be started as early as 30 days after the previous one, and a medical evaluation must be performed before starting each new course.

Dosing Principle

There is no advantage to increasing the dose in subsequent cycles if ovulation is achieved at the initial 50 mg dose. The dose of 100 mg is reserved exclusively for non-responders to the lower regimen, thereby establishing a specific dose-titration logic based on the patient's response.

Recent Clinical Evidence

Recent Clinical Evidence

Clinical research on Clomifene (also known as clomiphene citrate) focuses primarily on its established use in reproductive medicine and its investigation in specialized populations. Clomifene is a nonsteroidal selective estrogen receptor modulator (SERM) and is widely studied for ovulation induction in women who experience anovulatory or oligo-ovulatory infertility, such as those with Polycystic Ovary Syndrome (PCOS).

Core Research Findings

Phase 3 trials and long-term studies have reported on the outcomes associated with clomifene therapy. In clinical trials for ovulation induction, the rate of multiple pregnancies (e.g., twins, triplets) was noted in a minority of participants, which is a key measure tracked in this field of medicine.

Research Area Key Study Endpoint
Ovulation Induction Ovulation rates; Time to pregnancy; Conception rates
Combination Therapy Use alongside other fertility drugs (e.g., Letrozole) to evaluate rates of ovulation and pregnancy.

Specialized Populations

  • PCOS and Resistance: Studies continue to investigate clomifene in women with PCOS, particularly those who are resistant to the standard course of treatment. Research is exploring alternative or combined treatment strategies for this group.
  • Male Infertility: Clomifene is being investigated in men with certain types of infertility, specifically those with low sperm counts and associated low testosterone levels (hypogonadism). Studies have evaluated its influence on serum testosterone and semen parameters in this patient group.

Overall, the most comprehensive evidence remains in the area of female anovulatory infertility, though research is ongoing to clarify its profile in other reproductive health applications.

Key Studies & References

  1. NICE Guideline NG196: Fertility problems: assessment and treatment

Frequently Asked Questions (FAQ)

Common questions about Biogen (Clomifene) (FAQ)


Q: Is Biogen (Clomifene) the same thing as Clomid?

Yes, Clomid is a widely recognized brand name for the active ingredient clomiphene citrate, which is the same medicine found in Biogen. According to regulatory labeling, Clomiphene Citrate is the essential compound used to stimulate ovulation.


Q: How many cycles of Biogen (Clomifene) are usually needed?

Official guidelines recommend that treatment be limited to a total of about six cycles. Regulatory patient information also notes that most women who are going to benefit from the medicine typically do so within the first three treatment cycles.


Q: What happens if I forget to take a dose of Biogen (Clomifene)?

If a dose is missed, regulatory patient information generally advises against taking a double dose to make up for the one you missed. The recommended procedure is to contact a healthcare provider for specific instructions.


Q: Does Biogen (Clomifene) affect mood or cause emotional changes?

Official labeling includes reports of adverse events related to the central nervous system and psychiatric system. These documented effects include mood changes, anxiety, irritability, and depression, which are noted among postmarketing reports.


Q: What are the long-term effects of using Clomifene for multiple cycles?

The use of this medicine is officially restricted to about six total cycles due to limited safety data for durations beyond that. Available safety data does not suggest an increased risk of ovarian cancer when the drug is used for fewer than 12 cycles in a lifetime; however, use is officially restricted to about six total cycles.


Q: Does my age affect how Biogen (Clomifene) might work?

Regulatory documents state that the safety and effectiveness of clomiphene have not been established in the pediatric population (children and adolescents). Clinical data is also officially insufficient for the geriatric population (older adults) in its intended use.


Q: Can Clomifene affect the lining of the uterus?

Yes, as a hormonal modulator, Clomifene interacts with estrogen-receptor-containing tissues, which includes the endometrium (uterine lining). The adverse effects section in regulatory documents notes the potential for reduced endometrial thickness in some patients.


Q: What steps are involved in monitoring a patient taking Clomifene?

A pelvic examination is specified in regulatory warnings prior to treatment and again before each subsequent course. Additionally, periodic monitoring of plasma triglycerides (fats in the blood) is recommended for patients with a history of hyperlipidemia.


Q: Does Biogen (Clomifene) interact with alcohol?

Official patient information advises patients to discuss the use of alcohol with their healthcare professional, as alcohol use may be a factor in conception or side effects like dizziness.


Q: What are the most common things people worry about when taking Biogen?

According to official documentation, the most common documented adverse events are vasomotor flushing (hot flushes) and ovarian enlargement. Other frequently noted concerns include abdominal discomfort, headache, and visual disturbances, which are classified as common side effects.


Q: Does Biogen (Clomifene) always cause twins or multiple births?

No, it does not always cause multiple births, but the incidence of multiple births, typically twins, is officially documented as increased, occurring in a minority of pregnancies conceived during treatment.


Q: How quickly does Biogen (Clomifene) start working after the first cycle?

The medicine is designed to start a chain of hormonal events in the body. Official patient information indicates that this process typically culminates in ovulation 6–12 days after the course of treatment is completed.


Q: Is it normal to feel dizzy or lightheaded while on Biogen?

Dizziness is listed as an uncommon adverse event in the regulatory safety profile. Official labeling advises that caution is necessary because visual symptoms and central nervous system effects may affect activities like driving.


Q: Is it normal to feel bloated while taking Biogen (Clomifene)?

Official regulatory patient information classifies both bloating and general abdominal discomfort as common side effects of the medication. This is a common experience documented in clinical use.


Q: Are there foods or drinks that should be avoided while on Clomifene?

Official product information advises patients to discuss the use of the medicine with food with their healthcare professional. However, there are no specific official restrictions documented regarding the avoidance of particular foods or drinks.


Q: How does Biogen (Clomifene) compare to injectables, generally speaking?

Clomifene is classified as an oral, non-steroidal selective estrogen receptor modulator (SERM). Official warnings note that the risk profile for the severe form of Ovarian Hyperstimulation Syndrome (OHSS) is generally different with Clomifene compared to injectable gonadotropin medications.


Q: Is Biogen (Clomifene) recommended for people with unexplained infertility?

The medicine is officially indicated for the treatment of ovulatory dysfunction in women who are seeking pregnancy. Its official established use is for those with specific ovulatory problems, as noted in regulatory indications, and not specifically for unexplained infertility.


Q: What if Biogen (Clomifene) doesn't seem to work for me?

If ovulation does not occur after the initial course, the regulatory dosing principle allows the dose to be increased for the next course. If ovulation has not occurred after three total courses, regulatory guidelines advise that the underlying diagnosis should be reassessed.


Q: What happens to Biogen (Clomifene) in the body after it's taken?

According to the official pharmacokinetics section, the drug is readily absorbed orally. It is primarily eliminated from the body through the feces (around 42%), with a small amount excreted in the urine.


Q: Why do some people need higher doses of Biogen (Clomifene) than others?

The dose is generally increased from the initial level only for patients who did not ovulate following their previous course. This establishes a clear principle of response-based dose titration based on regulatory guidelines.


Q: Are generics of Clomifene equally effective as brand names like Biogen?

Government agencies require that generic versions of Clomiphene Citrate must demonstrate bioequivalence to the original reference drug. This process, using specific pharmacokinetic endpoints, is designed to ensure that generic products are therapeutically equivalent.


Q: What is the difference between Clomifene citrate and other forms?

Clomifene citrate is formulated as a citrate salt and is a racemic mixture of two geometric isomers: zuclomiphene and enclomiphene. Both isomers contribute to the overall therapeutic action as detailed in the official composition documents.


Q: How long does Clomifene stay in your system after stopping?

Official pharmacokinetics data indicates the medicine has an elimination half-life of approximately 5 to 7 days. However, regulatory reports confirm that one of the active isomers, zuclomiphene, may persist in the system for longer than a month in some patients.


Q: Is there a link between Biogen (Clomifene) use and an increased risk of cancer?

Official postmarketing reports include documented cases of various neoplasms (cancers). Safety information does not generally indicate an increased risk of ovarian cancer when the drug is used for less than 12 total cycles in a lifetime; however, use is officially restricted to about six total cycles.


Q: Can men use Biogen (Clomifene) for any reason?

The medicine is approved by the FDA only for the treatment of ovulatory dysfunction in women who are desiring pregnancy. It is not approved for men for any specific condition according to the official indications section.


Q: What does the research say about the overall effectiveness of Clomifene?

Regulatory-approved patient information notes that up to 80% of patients given Clomifene may ovulate. Approximately half of those who ovulate may conceive, though success rates vary based on the underlying cause of the disorder.


Q: Do I need a special prescription or specialist to get Biogen (Clomifene)?

Official warnings state that use should be supervised by a practitioner with training and who is thoroughly familiar with infertility problems and their management.


Q: Can Biogen (Clomifene) interact with herbal supplements?

Yes. Patients are advised in official interaction information to inform their care team if they are taking any herbs, non-prescription drugs, or dietary supplements. This is because some of these items, such as certain cohosh varieties, may interact with the medication.

How should Biogen (Clomifene) be stored and disposed of?

Official Storage and Disposal Requirements

Clomifene citrate tablets must be stored according to strict regulatory guidelines to maintain product stability and integrity.

Domain Official Regulatory Requirement
Temperature & Environment Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F) [1.1], [3.3]. The product must be protected from heat, light, and excessive humidity [3.3].
Container & Safety Keep the medicine in its original, closed container and store it out of the sight and reach of children [2.1], [3.6].
Disposal Do not dispose of unused or expired tablets via wastewater or household waste [2.1]. Disposal must follow local regulatory requirements for pharmaceutical waste [2.1].

Summary of Regulatory Constraints: Official labeling defines the mandatory storage environment as controlled room temperature, requiring protection from environmental factors like light and moisture [3.3]. The medicine must remain secured in its original packaging and must be kept out of the reach of children [2.1], [3.6]. Disposal of the product is restricted and requires adherence to local pharmaceutical waste procedures [2.1].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biogen (Clomifene) found in:

A-Z Index: